Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

DILAUDID Drug Profile

« Back to Dashboard

What is the patent landscape for Dilaudid, and what generic Dilaudid alternatives are available?

Dilaudid is a drug marketed by Fresenius Kabi Usa and Purdue Pharm Prods and is included in three NDAs. There is one patent protecting this drug and four Paragraph IV challenges.

This drug has seventeen patent family members in nine countries.

The generic ingredient in DILAUDID is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.

Summary for Tradename: DILAUDID

Patents:1
Applicants:2
NDAs:3
Suppliers / Packagers: see list8
Bulk Api Vendors: see list8
Clinical Trials: see list41
Patent Applications: see list5,084
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DILAUDID at DailyMed

Pharmacology for Tradename: DILAUDID

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-003Apr 30, 2009APRXYesYes6,589,960► SubscribeYY ► Subscribe
Purdue Pharm Prods
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL019892-001Dec 7, 1992ABRXYesYes6,589,960► SubscribeYY ► Subscribe
Purdue Pharm Prods
DILAUDID
hydromorphone hydrochloride
SOLUTION;ORAL019891-001Dec 7, 1992AARXYesYes6,589,960► SubscribeYY ► Subscribe
Fresenius Kabi Usa
DILAUDID-HP
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-001Jan 11, 1984APRXYesYes6,589,960► SubscribeY ► Subscribe
Fresenius Kabi Usa
DILAUDID
hydromorphone hydrochloride
INJECTABLE;INJECTION019034-004Apr 30, 2009APRXYesYes6,589,960► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Find generic sources and suppliers
  • Formulary management
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot